It was five years ago that Gilead Sciences Inc. paid $510 million for a deal that had a drug called momelotinib at the center of it. The drug had originally been designed to treat a bone marrow condition called myelofibrosis. Gilead sold the drug to Sierra Oncology for $3 million, who has other plans for … Continue reading “Gilead Paid $510 Million For This Drug But Sold it For Only $3 Million”
